19.3 Psilocybin-Assisted Therapy for MDD: Current Evidence and Clinical Considerations
No abstract is available for this record.
Bibliographic context
- Date
- 2022-09-30
- Source
- OpenAlex
- PubMed
- Unavailable
Topics and keywords
psilocybin DepressionAnxietyReceptor PharmacologyRandomized Controlled Trial Randomized Controlled Trial PsilocybinContext (archaeology)HamdPsychologyAdverse effectPsychiatryDepression (economics)Hamilton Rating Scale for DepressionMajor depressive disorderRandomized controlled trialMedicineClinical psychologyInternal medicineHallucinogenMoodAnxietyEconomicsBiologyMacroeconomicsPaleontology
Citation graph
0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.
Indexed papers citing this DOI
Related papers
COMBINATION OF PSILOCYBIN AND COGNITIVE BEHAVIORAL THERAPY IMPROVES OXYTOCIN LEVELS AND DEPRESSIVE SYMPTOMS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDERGenetics and Molecular Research · 2025-12-31Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trialBJPsych Open · 2023-06-30Could psilocin rescue chronic, stress-accelerated, transcriptional aging in brain?UKnowledge (University of Kentucky) · 2025-03-03